<H1>Chapter DOI: 10.1007/978-1-60327-829-4_31<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>64</td></tr><tr><td>Springer references</td><td>1</td></tr><tr><td>Non Springer references</td><td>63</td></tr><tr><td>BibStructured Count</td><td width="10%">63</td></tr><tr><td>BibUnstructured Count</td><td width="10%">1</td></tr><tr><td>DOI already available in SpringerLink</td><td>41</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_31</td><td>BibArticle</td><td>Lippman SM, Hong WK. Cancer prevention science and practice. Cancer Res 2002;62:5119&#8211;25.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR2_31</td><td>BibArticle</td><td>Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159&#8211;70.</td><td><a href=http://dx.doi.org/10.1016/S0092-8674(00)81333-1>10.1016/S0092-8674(00)81333-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3_31</td><td>BibArticle</td><td>Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415&#8211;28.</td><td><a href=http://dx.doi.org/10.1038/nrg962>10.1038/nrg962</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_31</td><td>BibArticle</td><td>Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 1993;7:139&#8211;46.</td><td><a href=http://dx.doi.org/10.1002/mc.2940070303>10.1002/mc.2940070303</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5_31</td><td>BibArticle</td><td>Sakr WA. Prostatic intraepithelial neoplasia: A marker for high-risk groups and a potential target for chemoprevention. Eur Urol 1999;35:474&#8211;8.</td><td><a href=http://dx.doi.org/10.1159/000019882>10.1159/000019882</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_31</td><td>BibArticle</td><td>Sporn MB, Suh N. Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer 2002;2:537&#8211;43.</td><td><a href=http://dx.doi.org/10.1038/nrc844>10.1038/nrc844</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_31</td><td>BibArticle</td><td>Parnes HL, House MG, Kagan J, Kausal DJ, Lieberman R. Prostate cancer chemoprevention agent development: The National Cancer Institute, Division of Cancer Prevention portfolio. J Urol 2004;171:S68&#8211;74; discussion S5.</td><td><a href=http://dx.doi.org/10.1097/01.ju.0000107220.64675.74>10.1097/01.ju.0000107220.64675.74</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8_31</td><td>BibArticle</td><td>Bostwick DG, Qian J. Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia. Urology 2001;58:91&#8211;3.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(01)01248-1>10.1016/S0090-4295(01)01248-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_31</td><td>BibArticle</td><td>De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985&#8211;92.</td><td><a href=http://dx.doi.org/10.1016/S0002-9440(10)65517-4>10.1016/S0002-9440(10)65517-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_31</td><td>BibArticle</td><td>Kronz JD, Allan CH, Shaikh AA, Epstein JI. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol 2001;25:1079&#8211;85.</td><td><a href=http://dx.doi.org/10.1097/00000478-200108000-00014>10.1097/00000478-200108000-00014</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_31</td><td>BibArticle</td><td>Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006;175:820&#8211;34.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)00337-X>10.1016/S0022-5347(05)00337-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_31</td><td>BibArticle</td><td>Godken N, Roehl KA, Catalona WJ, Humphrey PA. High-grade prostatic intraepithelial neoplasia in needle biopsy as risk factor for detection of adenocarcinoma: current level of risk in screening population. Urology 2005;65:538&#8211;42</td><td><a href=http://dx.doi.org/10.1016/j.urology.2004.10.010>10.1016/j.urology.2004.10.010</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_31</td><td>BibArticle</td><td>Langeberg WJ, Isaacs WB, Stanford JL. Genetic etiology of hereditary prostate cancer. Front Biosci 2007;12:4101&#8211;10.</td><td><a href=http://dx.doi.org/10.2741/2374>10.2741/2374</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14_31</td><td>BibArticle</td><td>Noe M, Schroy P, Demierre MF, Babayan R, Geller AC. Increased cancer risk for individuals with a family history of prostate cancer, colorectal cancer, and melanoma and their associated screening recommendations and practices. Cancer Causes Control 2008;19:1&#8211;12.</td><td><a href=http://dx.doi.org/10.1007/s10552-007-9064-y>10.1007/s10552-007-9064-y</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15_31</td><td>BibBook</td><td>Eastham J. Personal communication; 2009.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR16_31</td><td>BibBook</td><td>Carroll P. personal communication; 2008.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17_31</td><td>BibBook</td><td>Kumar NB. Personal communication; 2008.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR18_31</td><td>BibBook</td><td>Bosland MC. Personal communication; 2008.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19_31</td><td>BibBook</td><td>Kucuk O. Personal communication; 2006.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR20_31</td><td>BibBook</td><td>Bergan R. Personal communication; 2006.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21_31</td><td>BibBook</td><td>Ahmann FR. Personal communication; 2008.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR22_31</td><td>BibBook</td><td>El-Bayoumy K. Personal communication; 2008.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR23_31</td><td>BibBook</td><td>Marshall J. Personal communication; 2008.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR24_31</td><td>BibBook</td><td>Ip C. Personal communication; 2008.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR25_31</td><td>BibArticle</td><td>Sabichi AL, Lee JJ, Taylor RJ, et al. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res 2006;12:2178&#8211;84.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-05-0937>10.1158/1078-0432.CCR-05-0937</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26_31</td><td>BibBook</td><td>Kim J. Personal communication; 2007.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR27_31</td><td>BibArticle</td><td>Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians&#8217; Health Study II randomized controlled trial. JAMA 2009;301:52&#8211;62.</td><td><a href=http://dx.doi.org/10.1001/jama.2008.862>10.1001/jama.2008.862</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_31</td><td>BibBook</td><td>Gee J. Personal communication; 2008.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR29_31</td><td>BibBook</td><td>Wilding G. Personal communication; 2008.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR30_31</td><td>BibBook</td><td>Leibovich BC. Personal communication; 2007.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR31_31</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Carducci</span> <span style='background:#DDDDDD'>MA WJ</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Heath</span> <span style='background:#DDDDDD'>E</span></span>, et al.</aug> <span style='background:#CCCCFF'>A randomized, placebo-controlled trial of celecoxib in men prior to receiving prostatectomy for clinically localized adenocarcinoma of the prostate: Evaluation of drug-specific biomarker modulation</span>. <span style='background:#CCFF99'>J Clin Oncol</span> (ASCO Annu Meet Proc) <span style='background:#66FF66'>2007</span>;<span style='background:#FFFF0F'>25:235s</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR32_31</td><td>BibArticle</td><td>Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215&#8211;24.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa030660>10.1056/NEJMoa030660</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33_31</td><td>BibArticle</td><td>Simoneau AR, Gerner EW, Nagle R, et al. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2008;17:292&#8211;9.</td><td><a href=http://dx.doi.org/10.1158/1055-9965.EPI-07-0658>10.1158/1055-9965.EPI-07-0658</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34_31</td><td>BibBook</td><td>Nelson BJ. Personal communication; 2006.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR35_31</td><td>BibArticle</td><td>Tindall DJ, Rittmaster RS. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 2008;179:1235&#8211;42.</td><td><a href=http://dx.doi.org/10.1016/j.juro.2007.11.033>10.1016/j.juro.2007.11.033</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36_31</td><td>BibArticle</td><td>Parnes HL, Thompson IM, Ford LG. Prevention of hormone-related cancers: prostate cancer. J Clin Oncol 2005;23:368&#8211;77.</td><td><a href=http://dx.doi.org/10.1200/JCO.2005.08.027>10.1200/JCO.2005.08.027</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37_31</td><td>BibArticle</td><td>Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000;37:367&#8211;80.</td><td><a href=http://dx.doi.org/10.1159/000020181>10.1159/000020181</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38_31</td><td>BibArticle</td><td>Rennie PS, Bruchovsky N, McLoughlin MG, Batzold FH, Dunstan-Adams EE. Kinetic analysis of 5 alpha-reductase isoenzymes in benign prostatic hyperplasia (BPH). J Steroid Biochem 1983;19:169&#8211;73.</td><td><a href=http://dx.doi.org/10.1016/S0022-4731(83)80022-3>10.1016/S0022-4731(83)80022-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39_31</td><td>BibArticle</td><td>Thomas LN, Douglas RC, Lazier CB, et al. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol 2008;179:147&#8211;51.</td><td><a href=http://dx.doi.org/10.1016/j.juro.2007.08.155>10.1016/j.juro.2007.08.155</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40_31</td><td>BibArticle</td><td>Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1025&#8211;35.</td><td><a href=http://dx.doi.org/10.1093/jnci/djm023>10.1093/jnci/djm023</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41_31</td><td>BibArticle</td><td>Scardino PT. The prevention of prostate cancer &#8211; the dilemma continues. N Engl J Med 2003;349:297&#8211;9.</td><td><a href=http://dx.doi.org/10.1056/NEJMe038109>10.1056/NEJMe038109</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42_31</td><td>BibArticle</td><td>Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375&#8211;83.</td><td><a href=http://dx.doi.org/10.1093/jnci/djm117>10.1093/jnci/djm117</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43_31</td><td>BibArticle</td><td>Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006;98:1128&#8211;33.</td><td><a href=http://dx.doi.org/10.1093/jnci/djj307>10.1093/jnci/djj307</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44_31</td><td>BibArticle</td><td>Thompson IM, Tangen CM, Goodman PJ, et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 2007;177:1749&#8211;52.</td><td><a href=http://dx.doi.org/10.1016/j.juro.2007.01.071>10.1016/j.juro.2007.01.071</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45_31</td><td>BibArticle</td><td>Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98:529&#8211;34.</td><td><a href=http://dx.doi.org/10.1093/jnci/djj131>10.1093/jnci/djj131</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46_31</td><td>BibArticle</td><td>McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387&#8211;98.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa030656>10.1056/NEJMoa030656</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47_31</td><td>BibArticle</td><td>Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004;89:2179&#8211;84.</td><td><a href=http://dx.doi.org/10.1210/jc.2003-030330>10.1210/jc.2003-030330</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48_31</td><td>BibArticle</td><td>Lippman SM, Goodman PJ, Klein EA, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005;97:94&#8211;102.</td><td><a href=http://dx.doi.org/10.1093/jnci/dji009>10.1093/jnci/dji009</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49_31</td><td>BibArticle</td><td>Clark LC, Combs GF Jr., Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957&#8211;63.</td><td><a href=http://dx.doi.org/10.1001/jama.1996.03540240035027>10.1001/jama.1996.03540240035027</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50_31</td><td>BibArticle</td><td>Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90:440&#8211;6.</td><td><a href=http://dx.doi.org/10.1093/jnci/90.6.440>10.1093/jnci/90.6.440</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51_31</td><td>BibArticle</td><td>Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483&#8211;92.</td><td><a href=http://dx.doi.org/10.1093/jnci/85.18.1483>10.1093/jnci/85.18.1483</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52_31</td><td>BibArticle</td><td>Yoshizawa K, Willett WC, Morris SJ, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998;90:1219&#8211;24.</td><td><a href=http://dx.doi.org/10.1093/jnci/90.16.1219>10.1093/jnci/90.16.1219</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR53_31</td><td>BibArticle</td><td>Redman C, Scott JA, Baines AT, et al. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett 1998;125:103&#8211;10.</td><td><a href=http://dx.doi.org/10.1016/S0304-3835(97)00497-7>10.1016/S0304-3835(97)00497-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR54_31</td><td>BibArticle</td><td>Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 2000;9:1171&#8211;82.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR55_31</td><td>BibArticle</td><td>Li H, Stampfer MJ, Giovannucci EL, et al. A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 2004;96:696&#8211;703.</td><td><a href=http://dx.doi.org/10.1093/jnci/djh125>10.1093/jnci/djh125</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR56_31</td><td>BibArticle</td><td>Willett W. Lessons from dietary studies in Adventists and questions for the future. Am J Clin Nutr 2003;78:539S&#8211;43S.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR57_31</td><td>BibArticle</td><td>Coates RJ, Weiss NS, Daling JR, Morris JS, Labbe RF. Serum levels of selenium and retinol and the subsequent risk of cancer. Am J Epidemiol 1988;128:515&#8211;23.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR58_31</td><td>BibArticle</td><td>Knekt P, Aromaa A, Maatela J, et al. Serum vitamin E and risk of cancer among Finnish men during a 10-year follow-up. Am J Epidemiol 1988;127:28&#8211;41.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR59_31</td><td>BibArticle</td><td>Criqui MH, Bangdiwala S, Goodman DS, et al. Selenium, retinol, retinol-binding protein, and uric acid. Associations with cancer mortality in a population-based prospective case-control study. Ann Epidemiol 1991;1:385&#8211;93.</td><td><a href=http://dx.doi.org/10.1016/1047-2797(91)90008-Z>10.1016/1047-2797(91)90008-Z</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR60_31</td><td>BibArticle</td><td>Hsing AW, Comstock GW, Abbey H, Polk BF. Serologic precursors of cancer. Retinol, carotenoids, and tocopherol and risk of prostate cancer. J Natl Cancer Inst 1990;82:941&#8211;6.</td><td><a href=http://dx.doi.org/10.1093/jnci/82.11.941>10.1093/jnci/82.11.941</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR61_31</td><td>BibArticle</td><td>Comstock GW, Helzlsouer KJ, Bush TL. Prediagnostic serum levels of carotenoids and vitamin E as related to subsequent cancer in Washington County, Maryland. Am J Clin Nutr 1991;53:260S&#8211;4S.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR62_31</td><td>BibArticle</td><td>Eichholzer M, Stahelin HB, Gey KF, Ludin E, Bernasconi F. Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer 1996;66:145&#8211;50.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0215(19960410)66:2&lt;145::AID-IJC1&gt;3.0.CO;2-2>10.1002/(SICI)1097-0215(19960410)66:2&lt;145::AID-IJC1&gt;3.0.CO;2-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR63_31</td><td>BibArticle</td><td>Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 1999;8:893&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR64_31</td><td>BibArticle</td><td>Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39&#8211;51.</td><td><a href=http://dx.doi.org/10.1001/jama.2008.864>10.1001/jama.2008.864</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>